Stock IDIA IDORSIA LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Idorsia Ltd

Equities

IDIA

CH0363463438

Real-time Estimate Cboe Europe
Other stock markets
 06:15:15 2024-05-14 am EDT 		5-day change 1st Jan Change
2.254 CHF -2.51% Intraday chart for Idorsia Ltd +6.76% +6.05%
May. 07 Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds MT
May. 02 Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds
MT
Bondholders approve amended terms of the 2024 convertible bonds
GL
Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond
MT
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
GL
Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment
MT
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
GL
Idorsia publishes an invitation to a bondholder meeting
GL
Idorsia : On April 17, 2024, Idorsia published an Unaudited Financial Status as of March 31, 2024, in connection with an upcoming bondholder meeting. Unaudited Financial Status
PU
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
GL
Swiss Market Index Falls as ECB Signals June Rate Cut
MT
Idorsia to Revise July 2024 Convertible Bond Terms, Conditions
MT
Idorsia takes steps to address short-term liquidity needs
GL
Idorsia's Chief Medical Officer to Step Down at March-end; Successor Named
MT
Idorsia thanks Guy Braunstein for his years of service as he retires
GL
Transcript : Idorsia Ltd - Special Call
US FDA OKs Idorsia's Hypertension Treatment in Combination with Other Antihypertensive Drugs
MT
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
GL
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod
MT
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
GL
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IDIA Stock
  4. News Idorsia Ltd
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW